Galacto-oligosaccharides Stimulate the Growth of Bifidobacteria but Fail to Attenuate Inflammation in Experimental Colitis in Rats

Holma, Reetta; Juvonen, Petri; Asmawi, M. Z.; Vapaatalo, Heikki; Korpela, Riitta

doi:10.1080/003655202320378239

Cited by 72 publications

(39 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Active hexosecorrelated compound, a product prepared from the mycelium of edible Basidiomycete fungi and which contains oligosaccharides, also showed disease reduction in TNBS-induced colitis. 80,81 In contrast, treatment with galacto-oligosaccharides (GOS) had no effect, despite an increase of intestinal bifidobacteria, 82 indicating that an increase of these bacteria is not always associated with protection.…”

Section: Tnbs-induced Colitismentioning

confidence: 99%

Prebiotics in Chronic Intestinal Inflammation

Langen

Dieleman

2009

Inflammatory Bowel Diseases

156

107

View full text Add to dashboard Cite

Prebiotics are nondigestible fermentable fibers that are reported to have health benefits for the host. Older as well as more recent studies show beneficial effects in experimental colitis and lately also in human inflammatory bowel diseases (IBD), such as Crohn's disease, ulcerative colitis, and chronic pouchitis. In this review we give an overview of the benefits of prebiotics in rodent IBD models and in IBD patients and discuss their possible protective mechanisms. Commensal intestinal bacteria induce and perpetuate chronic intestinal inflammation, whereas others are protective. However, most of the current medications are directed against the exaggerated proinflammatory immune response of the host, some of them toxic and costly. Feeding prebiotics changes the composition of the intestinal microflora toward more protective intestinal bacteria and alters systemic and mucosal immune responses of the host. Therapy for IBD targeting intestinal bacteria and their function is just emerging. Prebiotics have the promise to be relatively safe, inexpensive, and easy to administer. Unraveling their protective mechanisms will help to develop rational applications of prebiotics. However, the initial promising results with dietary prebiotics in preclinical trials as well as small studies in human IBD will need to be confirmed in large randomized controlled clinical trials. Keywords ulcerative colitis; Crohn's disease; prebiotics; bifidobacteria; lactobacilli The incidence and prevalence of chronic inflammatory bowel diseases (IBD), such as Crohn's disease (CD) and ulcerative colitis (UC), are increasing in the developed northern hemisphere. Bernstein et al 1 recently published data that showed that Canada has the highest incidence and prevalence of CD thus far reported. The incidence rate for CD ranged from 8.8-20.2 per 100,000 and the prevalence ranged from 161-319 per 100,000. The incidence and prevalence of UC was lower, ranging from 9.9-19.5 and 162-249 per 100,000, respectively. Approximately 0.5% of the Canadian population has IBD. Several studies concerning the pathogenesis of IBD indicate that a combination of factors such as genetic susceptibility, intestinal microflora, dietary factors, intestinal barrier dysfunction, and an abnormal immune response to intestinal bacteria lead to chronic intestinal inflammation. CIHR Author Manuscript CIHR Author Manuscript CIHR Author Manuscript Current IBD TherapeuticsThe current medical armamentarium to treat UC and CD consists of 5-aminosalicylic acid (ASA) compounds, corticosteroids, azathioprine/6-mercaptopurine, methotrexate, and cyclosporine. Recently several biologics have been added to this list. 5 Most patients respond well to these therapies, but for some patients it is still inadequate and/or induces intolerable and serious side effects. In addition, the current therapies are mostly directed against the overly aggressive adaptive immune response of the host, but fail to correct potential environmental triggers such as the intestinal microflora that induces a...

show abstract

Section: Tnbs-induced Colitismentioning

confidence: 99%

Prebiotics in Chronic Intestinal Inflammation

Langen

Dieleman

2009

Inflammatory Bowel Diseases

156

107

View full text Add to dashboard Cite

show abstract

“…Inulin and oligofructose (125) or prebiotic treatment with germinated barley foodstuff (126) had beneficial effects on experimental colitis and the composition of the intestinal microflora of rats. Galactooligosaccharides, on the other hand, failed to attenuate inflammation in experimental colitis in rats (127).…”

Section: Effects Of Prebioticsmentioning

confidence: 99%

Probiotics and Prebiotics: Effects on Diarrhea1

Vrese¹,

Marteau

2007

The Journal of Nutrition

239

135

View full text Add to dashboard Cite

Probiotics have preventive as well as curative effects on several types of diarrhea of different etiologies. Prevention and therapy (or alleviation) of diarrhea have been successfully investigated for numerous dietary probiotics to establish probiotic properties and to justify health claims (the medicinal use of probiotic food and the therapy of gastrointestinal diseases itself may not be advertised under current food laws). Other probiotic microorganisms (e.g., Lactobacillus rhamnosus GG,

show abstract

“…This was probably because the inflammation in the acute phase of TNBS colitis was so extensive and severe due to the caustic properties of TNBS and ethanol, 14) besides the hapten-induced immunological modulation. 15) Even chemotherapy, using an inhibitor of neutrophil activation 16) and dexamethazone, 17) did not produce any significant effects when the treatment was initiated after the induction of colitis. Taken together, it is likely that, apart from the preventive effect, the acute phase of TNBS colitis is not suitable for examining any beneficial (therapeutic) effects of dietary factors.…”

mentioning

confidence: 99%